Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 83

1.

High-dose, frequently administered interferon beta therapy for relapsing-remitting multiple sclerosis must be maintained over the long term: the interferon beta dose-reduction study.

Barbero P, Verdun E, Bergui M, Pipieri A, Clerico M, Cucci A, Ricci A, Bergamasco B, Durelli L.

J Neurol Sci. 2004 Jul 15;222(1-2):13-9.

PMID:
15240190
2.
3.
4.

Dose and frequency of interferon treatment matter--INCOMIN and OPTIMS.

Durelli L.

J Neurol. 2003 Dec;250 Suppl 4:IV9-IV14. Review.

PMID:
14712396
5.

The importance of maintaining effective therapy in multiple sclerosis.

Durelli L, Clerico M.

J Neurol. 2005 Sep;252 Suppl 3:iii38-iii43. Review.

PMID:
16170500
6.

[Subcutaneous interferon-beta-1a in the treatment of multiple sclerosis].

Fertl E, Krichmayr M.

Wien Med Wochenschr. 2008;158(3-4):98-109. doi: 10.1007/s10354-008-0510-6. Review. German.

PMID:
18330526
7.

PRISMS: the story of a pivotal clinical trial series in multiple sclerosis.

Cohen BA, Rivera VM.

Curr Med Res Opin. 2010 Apr;26(4):827-38. doi: 10.1185/03007991003604018. Review. Erratum in: Curr Med Res Opin. 2010 Aug;26(8):1826. Dosage error in article text.

PMID:
20121658
8.

Early treatment and dose optimisation BENEFIT and BEYOND.

Hartung HP.

J Neurol. 2005 Sep;252 Suppl 3:iii44-iii50. Review.

PMID:
16170501
10.

Once weekly interferon beta for multiple sclerosis is superseded by higher and more frequent dosing.

Blumhardt LD.

Int J Clin Pract Suppl. 2002 Sep;(131):9-16. Review.

PMID:
12564807
11.
12.

Clinical efficacy, effects on MRI and tolerability of weekly intramuscular interferon-beta-1a in patients with MS and CIS.

Zivadinov R, Munschauer FE, Ramanathan M, Benedict RH, Weinstock-Guttman B.

Drugs Today (Barc). 2008 Aug;44(8):601-13. doi: 10.1358/dot.2008.44.8.1242250. Review.

PMID:
18846271
13.

Is multiple sclerosis a disease that requires frequent beta interferon dosing?

Durelli L.

J Neurol. 2004 Sep;251 Suppl 4:IV13-24. Review.

PMID:
15378303
14.

Interferon-β-1b: a review of its use in multiple sclerosis.

Plosker GL.

CNS Drugs. 2011 Jan;25(1):67-88. doi: 10.2165/11206430-000000000-00000. Review.

PMID:
21128695
15.

Rationale for early treatment with interferon beta-1a in relapsing-remitting multiple sclerosis.

Munschauer FE 3rd, Stuart WH.

Clin Ther. 1997 Sep-Oct;19(5):868-82. Review.

PMID:
9385476
16.

Disease-modifying therapy in relapsing--remitting multiple sclerosis: efficacy is paramount.

Cristiano E.

Int J Clin Pract Suppl. 2002 Sep;(131):3-7. Review.

PMID:
12564806
17.

Benefit-risk assessment of interferon-beta therapy for relapsing multiple sclerosis.

Francis G.

Expert Opin Drug Saf. 2004 Jul;3(4):289-303. Review. Erratum in: Expert Opin Drug Saf. 2004 Sep;3(5):505.

PMID:
15268647
18.

History of modern multiple sclerosis therapy.

Lublin F.

J Neurol. 2005 Sep;252 Suppl 3:iii3-iii9. Review.

PMID:
16170498
19.

Management of worsening multiple sclerosis with mitoxantrone: a review.

Fox EJ.

Clin Ther. 2006 Apr;28(4):461-74. Review.

PMID:
16750460
20.

Interferon-beta 1b in the treatment of multiple sclerosis.

Río J, Montalban X.

Expert Opin Pharmacother. 2005 Dec;6(16):2877-86. Review.

PMID:
16318438
Items per page

Supplemental Content

Write to the Help Desk